Japan: PMDA and the Ministry of Health, Labour and Welfare

The two-part system

Japan's regulation of medicines and medical devices is shared between two bodies. The Pharmaceuticals and Medical Devices Agency, known as the PMDA, is the technical review agency: it assesses the scientific evidence in marketing applications. Final approval authority rests with the Ministry of Health, Labour and Welfare, which grants marketing authorizations on the basis of those reviews.

In practice, sponsors file applications that the PMDA reviews, and the ministry issues the approval. Understanding which body does what matters for tracking where a product sits in the system.

How products enter the market

Prescription and over-the-counter medicines require a marketing approval based on quality, safety, and efficacy data. Generic medicines are assessed against the original approved product.

Medical devices are classified into four risk classes - I, II, III, and IV - aligned with the international harmonization model Japan helped develop. The route depends on the class: general low-risk devices need only a marketing notification, specified controlled devices follow a certification route through registered third-party certification bodies, and the highest-risk specially controlled devices require a full ministry approval after PMDA review.

A distinctive feature of the Japanese system is the requirement for a local marketing authorization holder - a licensed entity inside Japan responsible for the product - so foreign manufacturers cannot hold approvals directly without one.

Speeding access for serious disease

Japan operates several mechanisms to accelerate access. The SAKIGAKE designation system gives prioritized review and enhanced consultation to innovative products targeting serious conditions, especially those first developed in Japan. Conditional early approval allows marketing of promising products on the basis of preliminary evidence, with obligations to collect confirmatory data afterward.

These pathways reflect a deliberate policy of shortening the gap between when medicines reach patients in Japan and when they reach patients elsewhere.

Using this profile

Administrators and researchers should note that English-language access to Japanese regulatory information is limited: the review agency maintains an English portal, but detailed product and application records are primarily in Japanese. Product status is recorded through the approval and notification system rather than a single open register.

For cross-country comparison: Japan's four-class device model maps closely onto the international framework used in many countries, which makes device classification more transferable than drug approval mechanics. The authority portals listed in this profile's internal reference record are the primary sources for current rules.